Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Real Time Quote from BATS)
$34.80 USD
+0.77 (2.26%)
Updated Aug 8, 2024 10:00 AM ET
3-Hold of 5 3
C Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GPCR 34.80 +0.77(2.26%)
Will GPCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
IPO Round Up of First Half of 2023
Other News for GPCR
Buy Rating Affirmed: Undervalued Structure Therapeutics Poised for Growth with Strong R&D Pipeline and Strategic Partnerships
3 Biotech Stocks That Could Make Your Summer Unforgettable
Viking sends Lilly, Novo lower as obesity drug enters late-stage program
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Piper Sandler
Roche Is Raising The Efficacy Bar For The Oral GLP-1 Drug Class